Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efinaconazole in diabetic onychomycosis
NCT03168841Phase 3Completed
- Sponsor
- Western University of Health Sciences
- Start
- Jun 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of efinaconazole in onychomycosis, sponsored by Western University of Health Sciences. Primary endpoints: Mycological Cure Rate at 50 weeks, Complete Cure Rate at 50 weeks and 1 more. Started Jun 2017; status: completed.
02
Drugs
efinaconazole
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT03168841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168841.